Results 41 to 50 of about 28,931 (239)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls [PDF]

International Journal of Endocrinology and Metabolism, 2015
Depot preparations of gonadotropin-releasing hormone agonists (GnRHa) are the gold standard drugs for the treatment of central precocious puberty. A concern about these drugs is obesity.This study aimed to investigate the effect of gonadotropin-releasing hormone agonists (GnRHa) therapy on body mass index (BMI) in girls with central precocious puberty (
Shiasi Arani, Kobra, Heidari, Fatemeh
openaire   +2 more sources

Different Timing of Adjuvant Low Dose hCG and GnRH Agonist Trigger Protocol, in OHSS High-Risk Patient with Peak E2 Level <4000 pg/mL

Gynecology Obstetrics & Reproductive Medicine, 2020
OBJECTIVE: The aim of the study is to compare the live birth rates between 1,500 I.U. of Human chorionic gonadotropin at the time of Gonadotropin-releasing hormone agonist trigger day or 35-36 h later on the oocyte pick-up day, without affecting the ...
Emilija Zoran Petanovska Kostova, Velentina Sotirovska, Gligor Dimitrov, Snezana Stojkovska, Makjuli Hadzi Lega, Daniela Stojanovska, Nikoleta Stamenkovska, Liljana Simjanovska, Zoranco Petanovski   +8 more
doaj   +1 more source

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, EarlyView.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source

Safety, Pharmacokinetic and Pharmacodynamic Evaluation of Teverelix for the Treatment of Hormone-Sensitive Advanced Prostate Cancer: Phase 2 Loading-Dose-Finding Studies

Medicina, 2023
Background and objectives: Teverelix drug product (DP) is a gonadotropin-releasing hormone antagonist in development for the treatment of patients with prostate cancer in whom androgen deprivation therapy is indicated. The aim of this paper is to present
Carol M. MacLean, Albertas Ulys, Feliksas Jankevičius, Žilvinas Saladžinskas, Steve van Os, Finn Larsen   +5 more
doaj   +1 more source

Overnight levels of luteinizing hormone, follicle-stimulating hormone and growth hormone before and during gonadotropin-releasing hormone analogue treatment in short boys born small for gestational age [PDF]

, 2009
Aims: To evaluate if 3 months of gonadotropin-releasing hormone analogue (GnRHa) treatment results in sufficient suppression of pubertal luteinizing hormone (LH) and follicle-stimulating hormone (FSH) profile patterns in short pubertal small for ...
Bakker-Van Waarde, W.M. (Willie), Hokken-Koelega, A.C.S. (Anita), Jong, F.H. (Frank) de, Kaay, D.C.M. (Danielle) van der, Odink, R.J.H. (Roelof), Rose, S.R. (Susan), Sulkers, E.J. (Eric)   +6 more
core   +3 more sources

Natural Resistance to Ovarian Hyperstimulation Syndrome in Estrildid Finches Reveals Macrophage GPR183 as a Potential Therapeutic Target

Advanced Science, EarlyView.
Ovarian macrophage depletion reverses OHSS resistance in estrildid finches and exacerbates OHSS symptoms in rats. Activating macrophage GPR183 alleviates OHSS by reducing pro‐inflammatory factors, increasing immunomodulatory molecules, remodeling CD44/SDC4‐mediated communication, and restoring immune homeostasis.
Xiaofei Yan, Yongjie Huang, Jiabao Yang, Su Ma, Songsong Liu, Xuan Huang, Juergen Brosius, Huaping Zheng, Bing Yao, Li Chen, Shanshan Lai, Cheng Deng   +11 more
wiley   +1 more source

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy

Drug Design, Development and Therapy, 2023
Tomoyuki Tatenuma,1,2 Hiroshi Miyamoto1,3 1Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA; 2Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan ...
Tatenuma T, Miyamoto H
doaj  

Uterine Leiomyoma with Massive Lymphoid Infiltrate in a Patient with History of Assisted In-Vitro Fertilization

Türk Patoloji Dergisi, 2020
Uterine leiomyomas are the most common benign tumors of the gynecological tract. Massive lymphocytic infiltration has been reported rarely in uterine leiomyomas and it has been described as a pathogenetic correlation with gonadotropin-releasing hormone ...
Monia DI PRETE, Matteo COLLAMARINI, Claudio COLLAMARINI, Francesco SESTI, Alessandro MAURIELLO, Giampiero PALMIERI   +5 more
doaj   +1 more source

Individual 17-Hydroxyprogesterone Responses to hCG Are Not Correlated With Follicle Size in Polycystic Ovary Syndrome. [PDF]

, 2019
Context:In women with polycystic ovary syndrome (PCOS), 17-hydroxyprogesterone (17-OHP) responses to gonadotropin stimulation vary from increased to indistinguishable compared with normal controls.
Chang, R Jeffrey, Duleba, Antoni J, Garzo, Gabriel, Homer, Michael V, Lawson, Mark A, Toloubeydokhti, Tannaz   +5 more
core   +1 more source

Duplicated membrane estrogen receptors in the European sea bass (Dicentrarchus labrax): Phylogeny, expression and regulation throughout the reproductive cycle [PDF]

, 2018
The numerous estrogen functions reported across vertebrates have been classically explained by their binding to specific transcription factors, the nuclear estrogen receptors (ERs).
Alvarado, M. Victoria, Andrade, André, Estêvão, M. Dulce, Felip, Alicia, Pinto, Patricia IS, Power, Deborah   +5 more
core   +1 more source